EPO Use in Dialysis Patients with Cancer

Introduction to EPO Therapy

The American Society of Clinical Oncology and other guideline societies recommend that erythropoiesis-stimulating agents (ESAs) can be given to dialysis patients with cancer, but with significant caution due to increased risks of thromboembolism and potential tumor progression, with hemoglobin levels never exceeding 12 g/dL 1, 2

The FDA explicitly states that ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence, with a relative risk of thromboembolic events of 1.67 (95% CI: 1.35-2.06) compared to placebo 1, 2

The National Kidney Foundation recommends initiating EPO when hemoglobin is <10 g/dL in symptomatic patients, with iron deficiency corrected or supplementation initiated, and no contraindications present 7, 8
The European Renal Association suggests that the subcutaneous administration of EPO is 30-50% more efficient than the intravenous route, with a dosing regimen of 150 IU/kg subcutaneously three times weekly for epoetin alfa, and 2.25 μg/kg subcutaneously once weekly for darbepoetin alfa 4, 6

The American College of Cardiology recommends a target hemoglobin range of 10-12 g/dL, with dose reductions of 25-50% if hemoglobin rises >2 g/dL per 4 weeks or exceeds 12 g/dL, and holding therapy if hemoglobin exceeds 12 g/dL until it falls below 12 g/dL, then restarting at 25% lower dose 1, 2

The European Society of Medical Oncology suggests monitoring hemoglobin every 2-4 weeks during dose titration, then monthly once stable, with blood pressure monitored closely throughout therapy, and iron studies rechecked periodically as ESA therapy increases iron utilization and functional iron deficiency commonly develops 9

The American Society of Clinical Oncology recommends that several randomized trials have demonstrated decreased survival and poorer outcomes in cancer patients treated with ESAs, particularly when targeting hemoglobin >12 g/dL, with metastatic breast cancer patients on chemotherapy showing negative impact on overall survival 7, 8

The National Kidney Foundation recommends that baseline and periodic iron monitoring is essential, with correcting iron deficiency able to obviate the need for EPO or enhance its effectiveness, and instituting iron repletion when indicated to maximize response and limit EPO requirements 4, 5

The European Renal Association suggests never targeting hemoglobin >12 g/dL, as this significantly increases mortality and thrombotic risk, and not continuing EPO beyond 8 weeks without response, as this wastes resources and exposes patients to unnecessary risks 4, 6, 1, 2